Homologous recombination deficiency (HRD). An HRD test is being applied to patient samples to identify BRCA1/BRCA2 mutated tumors, provide a categorical determination of tumor HRD, and determine an enrichment strategy for patients with tumors that are sensitive to Niraparib treatment.
Suggested Pages #
- 0.025 HR
- 0.025 Non-homologous end joining
- 0.025 Mutational signature
- 0.025 February 13
- 0.025 Journal of Clinical Oncology
- 0.025 상동재조합
- 0.025
- 0.025 Michael Stratton
- 0.025 Cell-free tumor DNA
- 0.025 Tumor suppressor gene
- More suggestions...